Form 4: CRISPR Therapeutics Director Receives Stock Option Grant

Director Morrison Briggs was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard equity compensation.

Summary

• Director Morrison Briggs received a grant of 13,000 stock options for CRISPR Therapeutics AG common shares.
• The options have an exercise price of $51.84 per share.
• The grant date for these options is June 5, 2026.
• The options are set to expire on June 5, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• The grant aligns the director's long-term interests with those of the shareholders through equity-based compensation.

Negatives

• The issuance of new options results in potential future dilution for existing shareholders.

Risks

• The value of the options is dependent on the future market performance of the company's common shares.

Future Outlook

The options vest in 12 equal monthly installments, with the final installment vesting by the earlier of the one-year anniversary of the grant or the 2027 Annual Meeting, contingent upon continued service.

Management Comments

• The grant is subject to continued service to the Company or any of its subsidiaries.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board alignment with long-term corporate performance and shareholder value creation.

Comparison to Industry Standards

• The use of monthly vesting over one year is a common retention mechanism for board members in mid-to-large cap biotech firms.
• The grant size is consistent with typical director compensation packages for companies of similar market capitalization.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of the first installment of options on June 30, 2026.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Director, Stock Options, Equity Compensation, Insider Trading